Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

JPMorgan Cazenove gives AstraZeneca shares a boost, hiking its target price to 6,500p from 5,800p

JPMorgan’s analysts said the target hike comes after their updated their numbers to make “further upgrades to new launch trajectories, and include risk-adjusted forecasts for three further pipeline shots on goal”
They added: “We continue to see double-digit upside to consensus for new launch products in 2018 and 2019"

JPMorgan Cazenove gave a boost to AstraZeneca PLC (LON:AZN) on Thursday, with the drugmaker’s stock shrugging aside ex-dividend factors to push higher as the US bank hiked its target price and reiterated an ‘overweight’ stance.

The bank raised its target for the FTSE 100-listed shares to 6,500p, up from 5,800p previously, with the stock currently trading at 6,079p, up 1.5% on Wednesday’s close.

READ: AstraZeneca plots a return to growth as cancer portfolio boosts first-half performance

In a note to clients, JPMorgan’s analysts said the target hike comes after they updated their numbers for Astra following recent second quarter 2018 results, to make “further upgrades to new launch trajectories, and include risk-adjusted forecasts for three further pipeline shots on goal”.

They said: “We continue to see double-digit upside to consensus for new launch products in 2018 and 2019. Overall we make minor near-term forecast changes, with our 2019- 22e Core EPS CAGR unchanged at 19%; however our longer-term growth is further strengthened.”

The analysts noted that they continue to set their price target for AstraZeneca at a 50% premium to large cap-pharma peers, justified by a more than twice as fast medium-term outlook

They concluded: “With our PT implying double-digit upside, and with double-digit upside to consensus new launch expectations this year, as well as upcoming pipeline readouts with attractive risk/reward, we reiterate our Overweight.”

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use